MedTrace Logo

Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia

NCT02618057 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-04-27

No results posted yet for this study

Summary

Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia in children. The clinical course is typically self-limited and benign; however, rare cases of severe pneumonia can develop despite appropriate antibiotic therapy. The investigators aim to study the effects of prednisolone on severe M. pneumoniae pneumonia with lobar consolidation or pleural effusion in children.

Conditions

  • Mycoplasma Pneumoniae Pneumonia

Interventions

DRUG

Prednisolone

PO prednisolone, 1 mg/kg/day, for 5 days

DRUG

Levofloxacin

Levofloxacin, 10mg/kg/day, IV, for 5days

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Eun Hwa Choi, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618057 on ClinicalTrials.gov